that it has a cytolytic activity on pathogenic cells, said pathogenic cells being cells which are non-naturally occurring within the body consisting of microbial pathogenic organisms and malignant cells; and it is non-hemolytic, namely it has no cytolytic effect on red blood cells or has a cytolytic effect on red blood cells at concentrations which are substantially higher than that in which it manifests said cytolytic activity on pathogenic cells, said non-hemolytic cytolytic peptide being selected from the group consisting of:

(A) a cyclic derivative of a peptide having a net positive charge which is greater than +1, and comprising both L-amino acid residues and D-amino acid residues, or comprising only D-amino acid residues, and comprising an α-helix breaker moiety;

(B) a peptide comprising both L-amino acid residues and D-amino acid residues, having a net positive charge which is greater than +1, and having a sequence of amino acids such that the same amino acid sequence in which each residue is in the L-configuration is not found in nature, and cyclic derivatives thereof; and

(C) a random copolymer consisting of a hydrophobic, a positively charged and a D-amino acid,

with the proviso that the peptide is not that of SEQ ID NO:1.

14 (Five-Times-Amended). A cyclic derivative of a non-natural synthetic peptide according to claim 7, selected from the group of peptides consisting of those herein designated 92-95 (SEQ ID NOS:92-95, respectively), of the sequence:

92) Cyclic Cys Lys Leu **Leu** **Leu** Lys Leu Leu **Leu** Lys Leu Leu Lys Cys,

93) Cyclic Cys Lys Leu **Leu** **Leu** Lys Leu Lys **Leu** Lys **Leu** Lys Cys,

94) HN - Lys Leu **Leu** **Leu** Lys Leu Leu **Leu** Lys **Leu** Leu Lys - CO, and

95) HN - Lys Leu **Leu** **Leu** Lys Leu Lys **Leu** Lys **Leu** Leu Lys - CO.

31 (Twice-Amended). A composition comprising a pharmaceutically acceptable carrier and a peptide according to claim 1 in an anti-viral effective amount.

32(Amended). The composition of claim 31, wherein said antiviral effective amount is an amount effective to inhibit viral-induced hemolysis.

REMARKS

Claims 1-14, 20, 21, 27-35 and 37 presently appear in this case. Claims 1-14, 20, 21 and 27-34 have been rejected. Claims 35 and 37 have been objected to and, presumably, would be allowable if rewritten into independent